Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model

• URL: http://arxiv.org/abs/2209.07405v1
• Date: Sun, 14 Aug 2022 10:41:52 GMT
• Title: Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model
• Authors: Yaqin Li, Lingli Li, Yongjin Xu, and Yi Yu
• Abstract summary: Structure-based de novo method can overcome the data scarcity of active by incorporating drug-target interaction into deep generative architectures. Here, we demonstrate a widely used and fast protein sequence-based reinforcement learning model for drug discovery. As a proof of concept, the RL model was utilized to design molecules for four targets.
• Score: 4.815696666006742
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: De novo molecular design has facilitated the exploration of large chemical space to accelerate drug discovery. Structure-based de novo method can overcome the data scarcity of active ligands by incorporating drug-target interaction into deep generative architectures. However, these strategies are bottlenecked by the small fraction of experimentally determined protein or complex structures. In addition, the cost of molecular generation is computationally expensive due to 3D representations of both molecule and protein. Here, we demonstrate a widely used and fast protein sequence-based reinforcement learning (RL) model for drug discovery. In the generative model, one of the reward components, a binding affinity predictor, is based on 1D protein sequence and molecular SMILES. As a proof of concept, the RL model was utilized to design molecules for four targets. The generated compounds showed bioactivities by the validation of both QSAR and molecular docking with experimental 3D binding pockets. We also found that the performance of generated molecules depends on the selection of data source training for the binding predictor. Furthermore, drug design for a kinase without any experimental structure, CDK20, was studied by our model. With only 1D protein sequence as input, the generated novel compounds showed favorable binding affinity based on the AlphaFold predicted structure.

Related papers

• DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design [62.68420322996345]
  Existing structured-based drug design methods treat all ligand atoms equally. We propose a new diffusion model, DecompDiff, with decomposed priors over arms and scaffold. Our approach achieves state-of-the-art performance in generating high-affinity molecules.
  arXiv  Detail & Related papers  (2024-02-26T05:21:21Z)
• DiffDTM: A conditional structure-free framework for bioactive molecules generation targeted for dual proteins [35.72694124335747]
  DiffDTM is a conditional structure-free deep generative model based on a diffusion model for dual targets based molecule generation. We have conducted comprehensive multi-view experiments to demonstrate that DiffDTM can generate drug-like, synthesis-accessible, novel, and high-binding affinity molecules. The experimental results indicate that DiffDTM can be easily plugged into unseen dual targets to generate bioactive molecules.
  arXiv  Detail & Related papers  (2023-06-24T13:08:55Z)
• An Equivariant Generative Framework for Molecular Graph-Structure Co-Design [54.92529253182004]
  We present MolCode, a machine learning-based generative framework for underlineMolecular graph-structure underlineCo-design. In MolCode, 3D geometric information empowers the molecular 2D graph generation, which in turn helps guide the prediction of molecular 3D structure. Our investigation reveals that the 2D topology and 3D geometry contain intrinsically complementary information in molecule design.
  arXiv  Detail & Related papers  (2023-04-12T13:34:22Z)
• Multi-view deep learning based molecule design and structural optimization accelerates the SARS-CoV-2 inhibitor discovery [10.974317147338303]
  We propose MEDICO, a Multi-viEw Deep generative model for molecule generation, structural optimization, and SARS-CoV-2 Inhibitor disCOvery. We show that our MEDICO significantly outperforms the state-of-the-art methods in generating valid, unique, and novel molecules under benchmarking comparisons. Case study results on targeted molecule generation for the SARS-CoV-2 main protease (Mpro) show that by integrating molecule docking into our model as chemical priori, we successfully generate new small molecules with desired drug-like properties for the Mpro, potentially accelerating the de novo design of Covid
  arXiv  Detail & Related papers  (2022-12-03T08:21:13Z)
• State-specific protein-ligand complex structure prediction with a multi-scale deep generative model [68.28309982199902]
  We present NeuralPLexer, a computational approach that can directly predict protein-ligand complex structures. Our study suggests that a data-driven approach can capture the structural cooperativity between proteins and small molecules, showing promise in accelerating the design of enzymes, drug molecules, and beyond.
  arXiv  Detail & Related papers  (2022-09-30T01:46:38Z)
• Retrieval-based Controllable Molecule Generation [63.44583084888342]
  We propose a new retrieval-based framework for controllable molecule generation. We use a small set of molecules to steer the pre-trained generative model towards synthesizing molecules that satisfy the given design criteria. Our approach is agnostic to the choice of generative models and requires no task-specific fine-tuning.
  arXiv  Detail & Related papers  (2022-08-23T17:01:16Z)
• In-Pocket 3D Graphs Enhance Ligand-Target Compatibility in Generative Small-Molecule Creation [0.0]
  We present a graph-based generative modeling technology that encodes explicit 3D protein-ligand contacts within a relational graph architecture. The models combine a conditional variational autoencoder that allows for activity-specific molecule generation with putative contact generation that provides predictions of molecular interactions within the target binding pocket.
  arXiv  Detail & Related papers  (2022-04-05T22:53:51Z)
• Structure-aware generation of drug-like molecules [2.449909275410288]
  Deep generative methods have shown promise in proposing novel molecules from scratch (de-novo design) We propose a novel supervised model that generates molecular graphs jointly with 3D pose in a discretised molecular space. We evaluate our model using a docking benchmark and find that guided generation improves predicted binding affinities by 8% and drug-likeness scores by 10% over the baseline.
  arXiv  Detail & Related papers  (2021-11-07T15:19:54Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Benchmarking Deep Graph Generative Models for Optimizing New Drug Molecules for COVID-19 [11.853524110656991]
  Design of new drug compounds with target properties is a key area of research in generative modeling. We present a small drug molecule design pipeline based on graph-generative models and a comparison study of two state-of-the-art graph generative models for designing COVID-19 targeted drug candidates.
  arXiv  Detail & Related papers  (2021-02-09T17:49:26Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.